Spinal subpial gene delivery system

Patent metadata

Field	Value
Publication number	US-10688285-B2
Application number	US-201715790477-A
Country	US
Kind code	B2
Filing date	Oct 23, 2017
Priority date	Jan 30, 2015
Publication date	Jun 23, 2020
Grant date	Jun 23, 2020

Abstract

Delivery devices, systems, and methods related thereto may be used in humans for spinal delivery of cells, drugs or vectors. Thus, the system enables subpial delivery, which leads to a near complete spinal parenchymal AAV9-mediated gene expression or distribution in both white and grey matter.

First claim

What is claimed is:

1. A method of spinal trans-parenchymal infection of a nucleic acid molecule in a subject comprising administering a nucleic acid molecule to the subpial space of a subject, wherein the step of administering comprises:
(a) exposing a spinal segment of a vertebra of the subject;
(b) creating a pial opening within the spinal segment by penetrating the pia with a needle tip of a guide tube at an angle of about 5-10° relative to the pia;
(c) advancing a catheter through the guide tube into the subpial space; and
(d) delivering the nucleic acid molecule to the subpial space of the subject.

2. The method of claim 1 , wherein the nucleic acid molecule is administered in a mixture containing about 1-10% dextrose.

3. The method of claim 1 , wherein the nucleic acid molecule is a vector.

4. The method of claim 3 , wherein the vector is a lentiviral vector, adenoviral vector, or an adeno-associated vector.

5. The method of claim 4 , wherein the vector is an AAV9 particle.

6. The method of claim 5 , wherein the vector comprises a nucleic acid molecule encoding a protein or functional RNA that modulates or treats a neurodegenerative disorder.

7. The method of claim 6 , wherein the neurodegenerative disorder is amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, or Parkinson's disease.

8. The method of claim 1 , wherein the nucleic acid molecule is delivered as a single injection.

9. The method of claim 1 , further comprising administering one or more second subpial injections of the nucleic acid molecule into a different spinal segment of the vertebra of the subject by repeating steps (a)-(d).

10. The method of claim 1 , further comprising administering one or more intrathecal injections of the nucleic acid molecule to the subject.

11. The method of claim 1 , wherein the subject is a mammal.

12. The method of claim 11 , wherein the subject is human.

13. A method of delivering a nucleic acid molecule to the subpial space of a subject comprising:
(a) exposing a spinal segment of a vertebra of the subject;
(b) creating a pial opening within the spinal segment by penetrating the pia with a needle tip of a guide tube at an angle of about 5-10° relative to the pia;
(c) lifting the penetrated pia with the needle tip of the guide tube;
(d) advancing a catheter through the guide tube and into subpial space; and
(e) delivering a composition comprising the nucleic acid molecule through the catheter to the subpial space of the subject.

14. The method of claim 1 , further comprising withdrawing the guide tube prior to delivering the nucleic acid molecule to the subpial space of the subject.

15. The method of claim 13 , further comprising withdrawing the guide tube prior to delivering the nucleic acid molecule to the subpial space of the subject.

16. The method of claim 1 , wherein the needle tip of the guide tube is bent to about 90°.

17. The method of claim 6 , wherein the nucleic acid molecule encodes neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), aspartoacylase (ASPA), or amino acid decorboxylase (AADC).

18. The method of claim 6 , wherein the nucleic acid molecule encodes a functional RNA that inhibits the expression of SOD1.

19. The method of claim 13 , wherein the needle tip of the guide tube is bent to about 90°.

20. The method of claim 13 , wherein the nucleic acid molecule encodes a protein or functional RNA that modulates or treats a neurodegenerative disorder.

21. The method of claim 19 , wherein the nucleic acid molecule encodes neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), aspartoacylase (ASPA), or amino acid decorboxylase (AADC).

22. The method of claim 19 , wherein the nucleic acid molecule encodes a functional RNA that inhibits the expression of SOD1.

Assignees

• Univ California

Inventors

• Marsala Martin
• Miyanohara Atsushi

Classifications

• A61P25/26

  Psychostimulants, e.g. nicotine, cocaine · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N2750/14171

  Demonstrated in vivo effect · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title